EE04528B1 - Teraapias kasutatavad spirofuropridiinide aralklamiinid - Google Patents

Teraapias kasutatavad spirofuropridiinide aralklamiinid

Info

Publication number
EE04528B1
EE04528B1 EEP200100370A EEP200100370A EE04528B1 EE 04528 B1 EE04528 B1 EE 04528B1 EE P200100370 A EEP200100370 A EE P200100370A EE P200100370 A EEP200100370 A EE P200100370A EE 04528 B1 EE04528 B1 EE 04528B1
Authority
EE
Estonia
Prior art keywords
spirofurop
ridins
aralam
laminates
therapy
Prior art date
Application number
EEP200100370A
Other languages
English (en)
Inventor
Loch James Iii
Mullen George
Phillips Eifion
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200100370A publication Critical patent/EE200100370A/et
Publication of EE04528B1 publication Critical patent/EE04528B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
EEP200100370A 1999-01-15 1999-12-23 Teraapias kasutatavad spirofuropridiinide aralklamiinid EE04528B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9900100A SE9900100D0 (sv) 1999-01-15 1999-01-15 New compounds
PCT/SE1999/002478 WO2000042044A1 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy

Publications (2)

Publication Number Publication Date
EE200100370A EE200100370A (et) 2002-10-15
EE04528B1 true EE04528B1 (et) 2005-08-15

Family

ID=20414101

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100370A EE04528B1 (et) 1999-01-15 1999-12-23 Teraapias kasutatavad spirofuropridiinide aralklamiinid

Country Status (34)

Country Link
US (2) US6995167B2 (et)
EP (1) EP1147114B1 (et)
JP (1) JP2002534525A (et)
KR (1) KR100660496B1 (et)
CN (1) CN1132837C (et)
AR (1) AR022283A1 (et)
AT (1) ATE240960T1 (et)
AU (1) AU775433B2 (et)
BR (1) BR9916906A (et)
CA (1) CA2359990A1 (et)
CZ (1) CZ20012554A3 (et)
DE (1) DE69908185T2 (et)
DK (1) DK1147114T3 (et)
EE (1) EE04528B1 (et)
ES (1) ES2200590T3 (et)
HK (1) HK1040517B (et)
HU (1) HUP0200513A3 (et)
ID (1) ID30034A (et)
IL (1) IL144266A0 (et)
IS (1) IS6000A (et)
MY (1) MY118109A (et)
NO (1) NO20013478L (et)
NZ (1) NZ512733A (et)
PT (1) PT1147114E (et)
RU (1) RU2233282C2 (et)
SA (1) SA00200987B1 (et)
SE (1) SE9900100D0 (et)
SI (1) SI1147114T1 (et)
SK (1) SK9932001A3 (et)
TR (1) TR200102042T2 (et)
TW (2) TW200413387A (et)
UA (1) UA71598C2 (et)
WO (1) WO2000042044A1 (et)
ZA (1) ZA200105527B (et)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
DE60218032T2 (de) * 2001-06-01 2007-08-16 Astrazeneca Ab Neuer, für die therapie geeigneter ligand für nikotinische acetylcholinrezeptoren
DK1432707T3 (da) * 2001-10-02 2012-06-11 Pharmacia & Upjohn Co Llc Azabicyklisk-substituerede kondenserede heteroarylforbindelser til behandling af sygdomme
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
WO2003087103A1 (en) * 2002-04-18 2003-10-23 Astrazeneca Ab Thienyl compounds
EP1499618B1 (en) * 2002-04-18 2010-10-13 AstraZeneca AB Furyl compounds
NZ561993A (en) * 2002-04-18 2008-09-26 Astrazeneca Ab Spiroazabicyclic heterocyclic amines as potent ligands for nicotinic acetylcholine receptors
CA2495248A1 (en) 2002-08-30 2004-03-11 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
AU2003276919B2 (en) 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
DK1949901T3 (da) * 2002-12-06 2014-05-19 The Feinstein Inst Medical Res Fremgangsmåde til bestemmelse af en cholinerg agonist selektiv for en alfa-7-nikotinsk receptor
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
KR101063605B1 (ko) * 2003-01-08 2011-09-07 미쓰비시 타나베 파마 코퍼레이션 정신분열증 치료제
US20050129610A1 (en) * 2003-06-24 2005-06-16 Johns Hopkins University Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor
AU2004285751B2 (en) 2003-10-21 2008-07-24 Astrazeneca Ab Spirofuropyridine aryl derivatives
US7045530B2 (en) 2003-12-22 2006-05-16 Abbott Laboratories Spirocyclic quinuclidinic ether derivatives
CN103724343A (zh) 2004-03-25 2014-04-16 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
RU2448111C2 (ru) * 2006-08-21 2012-04-20 Дженентек, Инк. Соединения азабензофуранила и способ их применения
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
PE20110029A1 (es) 2008-06-20 2011-02-11 Astrazeneca Ab Derivados de dibenzotiazepina
KR101286323B1 (ko) 2008-10-17 2013-07-15 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물 및 치료제로서의 그의 용도
MY159826A (en) 2008-11-19 2017-02-15 Forum Pharmaceuticals Inc Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP5808319B2 (ja) * 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
MY165579A (en) * 2009-10-14 2018-04-05 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
CN105726531A (zh) 2010-02-26 2016-07-06 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
AR081402A1 (es) 2010-05-17 2012-08-29 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
EP2838902B1 (en) 2012-04-12 2018-12-05 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
CA2914263C (en) 2013-06-21 2021-05-18 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0311313B1 (en) * 1987-10-05 1995-05-10 Yamanouchi Pharmaceutical Co. Ltd. Heterocyclic spiro compounds and their preparation
JPH0195922A (ja) 1987-10-08 1989-04-14 Mazda Motor Corp 車両のサスペンション制御装置
BR9508751A (pt) * 1994-08-24 1997-08-12 Astra Ab Composto formulação e processos de tratamento ou profilaxia de disfunções psicóticas ou disfunções de debilitação intelectual e da ansiedade e de preparação do composto
CA2227695C (en) 1995-07-28 2008-02-12 Abbott Laboratories Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission
US6156783A (en) * 1996-04-30 2000-12-05 Smithkline Beecham P.L.C. Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
KR20010086167A (ko) 2001-09-08
US7196096B2 (en) 2007-03-27
AU2334300A (en) 2000-08-01
EP1147114B1 (en) 2003-05-21
IS6000A (is) 2001-07-12
IL144266A0 (en) 2002-05-23
HK1040517A1 (en) 2002-06-14
ZA200105527B (en) 2002-10-04
HK1040517B (zh) 2003-09-05
HUP0200513A2 (en) 2002-06-29
ATE240960T1 (de) 2003-06-15
WO2000042044A1 (en) 2000-07-20
ES2200590T3 (es) 2004-03-01
NO20013478L (no) 2001-09-14
CN1132837C (zh) 2003-12-31
AR022283A1 (es) 2002-09-04
RU2233282C2 (ru) 2004-07-27
UA71598C2 (en) 2004-12-15
DK1147114T3 (da) 2003-09-15
HUP0200513A3 (en) 2004-07-28
CZ20012554A3 (cs) 2002-01-16
SA00200987B1 (ar) 2006-11-07
CN1337964A (zh) 2002-02-27
CA2359990A1 (en) 2000-07-20
MY118109A (en) 2004-08-30
DE69908185T2 (de) 2004-06-03
US20050250802A1 (en) 2005-11-10
AU775433B2 (en) 2004-07-29
DE69908185D1 (de) 2003-06-26
TWI227237B (en) 2005-02-01
SK9932001A3 (en) 2002-04-04
ID30034A (id) 2001-11-01
US20030149065A1 (en) 2003-08-07
EP1147114A1 (en) 2001-10-24
TW200413387A (en) 2004-08-01
JP2002534525A (ja) 2002-10-15
NZ512733A (en) 2003-08-29
PT1147114E (pt) 2003-10-31
NO20013478D0 (no) 2001-07-13
EE200100370A (et) 2002-10-15
US6995167B2 (en) 2006-02-07
SI1147114T1 (en) 2003-12-31
TR200102042T2 (tr) 2002-05-21
BR9916906A (pt) 2001-10-30
KR100660496B1 (ko) 2006-12-22
SE9900100D0 (sv) 1999-01-15

Similar Documents

Publication Publication Date Title
EE04528B1 (et) Teraapias kasutatavad spirofuropridiinide aralklamiinid
AR028622A1 (es) Derivados de tropano utiles en terapia
GB0016787D0 (en) Compounds useful in therapy
DK1637127T3 (da) Terapeutisk mikroskum
GB9912411D0 (en) Compounds useful in therapy
DE60018978D1 (de) Benutzerauthentifiezierung in medizinischen systemen
ID26427A (id) Lembaran lentur yang digunakan dalam pakaian sekali pakai
GB0206033D0 (en) Compounds useful in therapy
GB9912413D0 (en) Compounds useful in therapy
NO20022692D0 (no) Terapeutiske midler
DE60014226T8 (de) Laminiervorrichtung
DE60019864D1 (de) Lasertherapiegerät
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
GB9912410D0 (en) Compounds useful in therapy
DE60012837D1 (de) Laminiervorrichtung
GB9912415D0 (en) Compounds useful in therapy
NO20016301D0 (no) Terapeutiske midler
EE200300025A (et) CRF2 ligandid kasutamiseks kombineeritud ravis
GB9906130D0 (en) Compounds for use in therapy
GB0014046D0 (en) Compounds useful in therapy
GB9911238D0 (en) Therapeutic use
GB9910772D0 (en) Compounds useful in therapy
GB9910769D0 (en) Compounds useful in therapy
GB9921314D0 (en) Compounds useful in therapy
GB9910767D0 (en) Compounds useful in therapy

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20081223